4. INDUSTRY PROFILE
The Indian Pharmaceutical Industry today is in the first
rank of India’s science based industries.
The Indian Pharma Industry is estimated to be worth $
4.5 billion, growing at about 8 to 9 percent annually.
The Indian Pharmaceutical sector is highly fragmented
with more than 20,000 registered units.
5. COMPANY PROFILE
Ranbaxy Laboratories Limited, India's largest
pharmaceutical company.
Ranked 8th amongst the global generic pharmaceutical
companies.
The Company has a global footprint in 49 countries.
World-class manufacturing facilities in 11 countries and
serves customers in over 125 countries.
R&D has a pool of over 1,200 scientists engaged in
research.
6. Perhaps the largest front-end in the generic industry
BRICS Other Emerging
Markets
• No. 1 in India • 43/54 countries in Africa
• Large, reputed player in • Latam & Asia Pacific:
CIS; growing rapidly long standing presence;
• No. 6 in Brazil good understanding;
• No. 5 in S. Africa robust businesses
North America & Europe
Japan
• Pioneer entrant from • Well established
India • 23/25 EU markets
• Strong local presence • No. 1 Generic player in
• Canada: New market, Romania
growing rapidly
Ground presence in 49 countries; products sold in 125
7. MISSION
To become a research
based international
pharmaceutical company.
8. VISION
Achieving customer satisfaction is fundamental to our business.
Provide product and service of the highest quality.
Manage our operation with high concern for strategy and
environment.
Be a responsible corporate citizen
9. MILESTONES
Ranbaxy entered in Golden Jubilee year.
For the year 2008, the Company recorded Global Sales of US $
1,682 Mn
Ranbaxy launches First to file (FTF) product , Donepezil
hydrochloride Tablets 5 mg and 10 mg with 180 days market
exclusively in the U.S. healthcare system.
Ranbaxy delivered quarterly sales of over US $ 500Mn for the
first time.
12. Strengths Weakness
• Low cost of production • Low on Capital Goods
• Efficient technology for • Low on key R&D
large no. of Generics • Less usage Bio-
• Skilled manpower technology for New Drug
Discovery Systems
Opportunities Threats
• Growing attention for health • High cost of discovering new
• New therapy approaches products
• Globalization • Stricter registration
• Growing income-levels procedures
• High entry cost in new
markets
13. Among top 10 Global generic drugs company.
Manufacturing operations in 11 countries, ground
presence in 49 countries and serves 125+ countries.
Expanding international portfolio of affiliates and JVs
International business generate 80% sales.
Strong market presence and distribution network.
State-of-the-art multi-disciplinary research facilities.
14. Flexible
and efficient supply chain structure ensures
stable access to raw materials, systematic
manufacturing and timely, reliable delivery.
Ranbaxy- Daiichi Sankyo Tie-up
Ranbaxy- access to Daiichi’s expertise in research
Daiichi - benefit from low-cost production
19. EMPLOYER EXPECTATION
Good working condition
Employee satisfaction toward salary.
Proper assigned of works and goals.
20. RETENTION POLICY
Training programs
Management trainee programs.
Through salaries and various other benefit.
21. TRAINING AND DEVELOPMENT
There basic is to understand the business through
lecturer and interactive session.
Project work in various areas of the key
function, across different location.
Self –awareness session also provided.
Self development with training on key behavior
attitudes.
22. PERFORMANCE APPRAISAL
It is used as a to measure the performance of employee
s in the organization to check the progress towards the
desired goals and aims.
Performance appraisal helps to rate the performance of
the employees and evaluate their contribution towards
the organizational goals.
Performance appraisal takes into account the past
performance of the employees and focuses on the
improvement of the future performance of the
employees.
23. HEALTH AND SAFETY MEASURE
They are totally committed to maintain high
standards of health and safety at the
workplace .
They try to be sensitive to protection of the
environment by responsible management of
waste and pollution.
26. Revenue Breakdown
Global Revenue RoW
$1,667 $203, +6 Asia
$1,619 Europe
$1,400 % $465, +3
$1,339 $328, -
%
10%
North
America
CIS $443
2006 2007 2008 2009 (F)* $111, +24 , +6%
%
Favourable Market Mix
Revenues spread across geographies
Growing share of high growth, sustainable branded
business in Emerging Markets
Substantial presence in regulated, western markets: high
volume base business + large Para-IV / FTF opportunities
27. COST DRIVERS
Raw material
R&D
Patent of product ( Process patent & Drug patent)
Packaging
Logistics
Ware housing ( self & contracted )
